Échéancier de négociation
-
Initiation
A drug is identified and brought into a pCPA process (see standard negotiation process or expedited negotiation pathways).
-
Consideration
The pCPA considers the evidence (including HTA reimbursement recommendations) and gathers other data to inform the negotiation approach, in alignment with the needs of public drug plans. This phase concludes when the pCPA sends a letter of engagement to the manufacturer.
-
Negotiation
The pCPA negotiation team reaches out to the manufacturer to outline next steps, then we exchange offers to try to reach an agreement on terms and funding conditions.
-
Completion
The pCPA creates a letter of intent outlining negotiated terms. If the negotiation ended without an agreement, the pCPA sends a letter letting the manufacturer know that the negotiation is closed.
Negotiation process concluded